title: Relationship between insulin-like growth factors (IGF-I and IGF-II), IGF-binding proteins (IGFBP-3, IGFBP-2), leptin and anthropometric parameters (height, body mass index) during antileukaemic treatment in children.
abstract: OBJECTIVE
  The aim of the study was to estimate the anthropometric parameters and their relationship to serum levels of IGF-I, IGF-II, IGFBP-3, IGFBP-2 and leptin before and during intensive antineoplastic treatment for acute lymphoblastic leukaemia in children.
  
  
  METHODS
  In 46 children in median age 6.6 years (range from 1.6 to 16) we evaluated at the time of diagnosis, after protocol I and after intensive treatment, height, body mass index (BMI) and IGF-I, IGF-II, IGFBP-3, IGFBP-2 and leptin.
  
  
  RESULTS
  Height SDS lowered in successive points of analysis whereas BMI SDS rose after protocol II. IGF-I SDS was low and similar at each point, IGF-II SDS and IGFBP-3 SDS values augmented progressively and IGFBP-2 SDS was significantly elevated before treatment and lowered (but not normalized) during the therapy. Leptin SDS was elevated, especially after protocol I.
  
  
  CONCLUSIONS
  Leukaemia and its treatment affect directly growth factors, its binding proteins and leptin production leading to growth retardation and overweight.
authors.affiliation: Department of Pediatric Oncology, Medical University of Białystok, Poland. rybak@amb.edu.pl
authors.forename: M
authors.initials: M
authors.lastname: Krawczuk-Rybak
authors.forename: K
authors.initials: K
authors.lastname: Muszyńska-Rosłan
authors.forename: A
authors.initials: A
authors.lastname: Kitszel
authors.forename: M
authors.initials: M
authors.lastname: Sawicka-Zukowska
authors.forename: S
authors.initials: S
authors.lastname: Wołczyński
mesh_terms: D000293:Adolescent; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001824:Body Constitution; D001827:Body Height; D002648:Child; D002675:Child, Preschool; D005260:Female; D006130:Growth Disorders / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D007223:Infant; D018971:Insulin-Like Growth Factor Binding Protein 2 / Q000097:blood*; D018972:Insulin-Like Growth Factor Binding Protein 3 / Q000097:blood*; D007334:Insulin-Like Growth Factor I / Q000378:metabolism*; D007335:Insulin-Like Growth Factor II / Q000378:metabolism*; D020738:Leptin / Q000097:blood*; D008297:Male; D050177:Overweight; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000097:blood* / Q000188:drug therapy
chemical_list: D000970:Antineoplastic Agents; D018971:Insulin-Like Growth Factor Binding Protein 2; D018972:Insulin-Like Growth Factor Binding Protein 3; D020738:Leptin; D007334:Insulin-Like Growth Factor I; D007335:Insulin-Like Growth Factor II